Shots:

• The P-III RELAY study involves assessing of Cyramza + erlotinib vs PBO + erlotinib in 449 patients with EGFR mutated mNSCLC across North America- EU- and Asia
• The P-III RELAY trials resulted in meeting its 1EPs & 2EPs and is safe & effective with no major AEs
• Cyramza (ramucirumab) is an antiangiogenic therapy active against VEGF-2 receptor. Lilly plans to make a global regulatory submission in H2’19 and submitted in the US- EU & Japan for hepatocellular carcinoma

Ref: Eli Lilly | Image: Eli Lilly